These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 22784693)

  • 1. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
    Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.
    Perez-Lloret S; Rey MV; Fabre N; Ory F; Spampinato U; Brefel-Courbon C; Montastruc JL; Rascol O
    Clin Neuropharmacol; 2012; 35(6):261-5. PubMed ID: 23123689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impulse control disorders and depression in Finnish patients with Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Voon V; Kaasinen V
    Parkinsonism Relat Disord; 2012 Feb; 18(2):155-60. PubMed ID: 21983019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.
    Poletti M; Logi C; Lucetti C; Del Dotto P; Baldacci F; Vergallo A; Ulivi M; Del Sarto S; Rossi G; Ceravolo R; Bonuccelli U
    J Clin Psychopharmacol; 2013 Oct; 33(5):691-4. PubMed ID: 23857310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impulse control disorders in Parkinson's disease in a Chinese population.
    Fan W; Ding H; Ma J; Chan P
    Neurosci Lett; 2009 Nov; 465(1):6-9. PubMed ID: 19560522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease.
    Valença GT; Glass PG; Negreiros NN; Duarte MB; Ventura LM; Mueller M; Oliveira-Filho J
    Parkinsonism Relat Disord; 2013 Jul; 19(7):698-700. PubMed ID: 23611687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term follow-up of Parkinson's disease patients with impulse control disorders.
    Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
    Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.
    Limotai N; Oyama G; Go C; Bernal O; Ong T; Moum SJ; Bhidayasiri R; Foote KD; Bowers D; Ward H; Okun MS
    Int J Neurosci; 2012 Mar; 122(3):145-53. PubMed ID: 22023411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease.
    Avanzi M; Uber E; Bonfà F
    Neurol Sci; 2004 Jun; 25(2):98-101. PubMed ID: 15221629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.
    Weintraub D; Sohr M; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
    Ann Neurol; 2010 Dec; 68(6):963-8. PubMed ID: 21154480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist.
    Auyeung M; Tsoi TH; Tang WK; Cheung CM; Lee CN; Li R; Yeung E
    Parkinsonism Relat Disord; 2011 Sep; 17(8):635-7. PubMed ID: 21705258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
    Weintraub D; Koester J; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
    Arch Neurol; 2010 May; 67(5):589-95. PubMed ID: 20457959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonist withdrawal syndrome in Parkinson disease.
    Rabinak CA; Nirenberg MJ
    Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication-related impulse control and repetitive behaviors in Parkinson's disease.
    Voon V; Potenza MN; Thomsen T
    Curr Opin Neurol; 2007 Aug; 20(4):484-92. PubMed ID: 17620886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current treatment strategies for Parkinson's disease].
    Südmeyer M; Wojtecki L; Schnitzler A
    Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168
    [No Abstract]   [Full Text] [Related]  

  • 19. [Impulse control disorders in Parkinson's disease].
    Joutsa J; Kaasinen V
    Duodecim; 2013; 129(22):2351-8. PubMed ID: 24397147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
    Wilson L; Sheehan J; Thorpe M
    Ir Med J; 2013 Jan; 106(1):24-5. PubMed ID: 23472375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.